Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Condensed Consolidated Statements Of Operations    
Revenues
Operating expenses:    
General and administrative expenses 133,353 98,011
Total operating expenses 133,353 98,011
Loss from operations (133,353) (98,011)
Other income (expense):    
Gain on non-related party share issuances 2,250
Gain/(Loss) on fair value adjustment - derivatives (313,419)
Interest expense (45,527) (64,212)
Interest expense - beneficial conversion feature 3,500 (6,250)
Total other income (expense) (355,446) (68,212)
Loss before provision for income taxes (488,799) (166,223)
Provision for income tax
Net loss (488,799) (166,223)
Less: Net loss attributable to noncontrolling interest 965 1,071
Net loss attributable to TranBioTec, Inc. $ (487,834) $ (165,152)
Net loss per share    
(Basic and fully diluted) $ (0.007) $ (0.003)
Weighted average number of common shares outstanding 74,200,854 66,020,299